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Objectives. This study sought o evaluate the effect of adenosine 
receptor blockade by aminophylline on cardiac functional reserve 
in patients with syndrome X. 
Background. Aminophylline may have a potentially anti- 
ischemic effect hrough the inhibition of adenosine and, thus, the 
coronary steal phenomenon i  patients with syndrome X. 
Methods. A single-blind, placebo-controlled study of an intra- 
venous infusion of aminophylline (6 mg/kg body weight over 
15 min) or placebo (20 ml of saline solution over 15 min) was 
performed uring continuous radionuclide monitoring of left 
ventricular ejection fraction in 12 patients performing supine 
bicycle rgometric exercise. 
Results. Aminophylline increased exercise time (aminophylline 
400 s vs. placebo 355 s, p < 0.01), decreased degree of ST segment 
depression (aminophylline 1.6 mm vs. placebo 2.4 ram, p < 0.01) 
and either abolished (seven patients) or diminished (five patients) 
chest pain during exercise. Aminophylline also increased left 
ventricular ejection fraction at rest (aminophylline 66.5% vs. 
placebo 62.3%, p < 0.05) but did not improve its deterioration at 
peak exercise (aminophylline 60.1% vs. placebo 56.6%, p = NS) or 
shorten the abnormally prolonged interval between the end of 
exercise and the overshoot (aminophylline 115 s vs. placebo 130 s, 
p = NS). 
Conclusions. Aminophylline infusion increases ischemic 
threshold and prolongs exercise duration in patients with syn- 
drome X. It is hypothesized that aminophylline acts by inhibit- 
ing the coronary steal phenomenon through adenosine receptor 
blockade. It does not improve the deterioration in left ventricular 
function at peak exercise or the delayed response in ejection 
fraction in the recovery period, presumably because the beneficial 
effects of aminophylline that result from the redistribution of 
coronary blood flow are limited. 
(J Am CoU Cardiol 1995;25:1547-51) 
Aminophylline, a competitive antagonist of adenosine, may 
have a potential beneficial effect on stress-induced ischemia in 
patients with coronary artery disease (1-5). Intravenous amino- 
phylline may prevent or delay the coronary steal phenomenon, 
which is caused by inappropriate adenosine release, and may 
thereby increase the ischemic threshold and prolong exercise 
duration (1-5). Syndrome X is characterized by exercise- 
induced anginal pain and ST segment depression, normal 
findings on coronary angiography and normal eft ventricular 
function at rest (6,7). Reduced coronary flow reserve and the 
coronary steal phenomenon have been proposed as causes of 
syndrome X (8-12). Recently, Emdin et al. (13) hypothesized 
that blocking adenosine receptors, which cause excessive cor- 
onary arteriolar dilation, might have beneficial effects on 
exercise capacity in patients with syndrome X. They demon- 
strated remarkable improvement in effort duration, chest pain 
and ischemic ST segment changes in these patients after 
aminophylline infusion. Although their data were impressive 
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and interesting, their hypothesis was still speculative (14), and 
the physiologic effects of aminophylline, including effects on 
left ventricular function during exercise (15), remained to be 
established. 
In the present study, we evaluated the effects of amino- 
phylline on cardiac functional reserve in patients with syn- 
drome X and explored its mechanism of action. The influence 
of aminophylline on left ventricular ejection fraction during ST 
segment depression, peak exercise and recovery was monitored 
continuously using an ambulatory ventricular function monitor 
(VEST) (16). 
Methods  
Study patients. Twelve patients (10 women, 2 men; mean 
age 53 years, range 42 to 64) with typical stress-induced angina 
and positive xercise test results limited by angina with >l-ram 
horizontal or downsloping ST segment depression at 80 ms 
after the J point were studied. All had angiographically normal 
coronary arteries, normal global and regional ventricular func- 
tion at baseline and absence of coronary artery spasm on 
ergonovine or acetylch01ine testing. No patient had left or right 
bundle branch block, systemic hypertension, diabetes mellitus 
or valvular heart disease. Written informed consent was ob- 
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Table 1. Clinical and Electrocardiographic Findings After Aminophylline or Placebo Infusion 
Time: EP (s) Time: OS (s) Max ST dep (ram) Anginal pain Reason for Term. 
Pt No. Age (yr)/Gender Placebo Amino Placebo Amino Placebo Amino Placebo Amino Placebo Amino 
1 42/F 360 420 100 80 2.5 2.0 Mild None E E 
2 42/F 360 420 140 140 1.5 1.0 Mild None E E 
3 45/F 300 360 100 120 2.0 1.0 Moderate None E E 
4 48/F 360 360 100 100 2.5 2.0 Moderate Mild E E 
5 48/M 600 720 160 140 4.0 2.5 Mild None E E 
6 54/F 360 420 160 80 2.0 1.5 Severe Mild P E 
7 56/F 360 480 120 120 3.0 2.0 Moderate None E E 
8 57/M 480 480 140 140 2.5 2.0 Mild None E E 
9 60/F 360 360 180 120 3.5 1.5 Mild None E E 
10 61/F 300 360 120 80 1.5 1.0 Moderate Mild E E 
11 63/F 240 240 140 140 2.5 1.0 Severe Mild P E 
12 64/F 180 240 100 120 1.5 1.5 Moderate Mild E E 
Mean +SE 53 + 2 355 -+ 31 400 + 36 130 ~ 8 115 _+ 7 2.4 _+ 0.2 1.6 _+ 0.1 
p value < 0.01 NS < 0.01 
Amino = aminophylline; E : muscular exhaustion; EP = end point; F = female; M : male; Max ST dep : maximal ST depression; OS = overshoot; P = chest 
pain; Pt = patient; Term. : termination of exercise. 
rained before patients entered the study, and the protocol was 
approved by our institution. 
Study design. Patients performed two consecutive exercise 
stress tests with an intervening 30-rain recovery interval. 
Before each test, they received, in a randomized single- 
blind crossover manner, an infusion of placebo (20 ml of saline 
solution over 15 rain) or aminophylline (6 mg/kg body weight 
over 15 rain). Exercise was started 5rain after the termination 
of each infusion. 
Assessment of chest pain. At the beginning of each test, 
patients were informed that they could develop chest pain. 
The patients assessed the severity of chest pain using a 
four-point scale (none, mild, moderate, severe). Moderate pain 
was defined as the chest pain that the patient usually experi- 
ences during exercise, and m//d or severe pain as less or more 
intense than usual. 
Exercise stress testing. The patient's red blood cells were 
labeled with 740 to 925 MBq (20 to 25 mCi) of technetium-99m 
using a modified in vivo method (17). With the patients supine, 
the VEST detector was positioned under a gamma camera to 
cover the left ventricle as previously described (18). The 
electrocardiographic (ECG) electrodes were positioned to 
record a standard 12-lead ECG. 
Patients performed supine bicycle ergometer xercise with 
an initial workload of 25 W and increasing increments of25 W 
every 2 rain. A 12-lead ECG and systolic and diastolic pres- 
sures were recorded at l-rain intervals during the test. Criteria 
for terminating the test were as follows: 1) _>4.0-ram ST 
segment depression at 80 ms after the J point; or 2) severe 
chest pain or muscular exhaustion or maximal heart rate for 
age, alone or in combination. To avoid a bias problem, all 
patients were informed that they could not terminate exercise 
except for muscular exhaustion or severe chest pain. All data 
were recorded within 10 rain after the termination ofexercise. 
We defined the following three time points during the 
course of exercise testing: 1) rest; 2) the end point; and 3) 
overshoot, defined as the rapid ejection fraction increase just 
after exercise (19,20). 
Data analysis. The VEST recorded sequential 50-ms ra- 
dionuclide missions from the left ventricle through the detec- 
tor and transferred the data to a personal computer (LTll, 
NEC, Inc.). End-diastolic and end-systolic counts were calcu- 
lated every 20 s as the sum of the nuclear data collected uring 
that interval. Data analysis consisted of evaluating the radio- 
nuclide data for technical adequacy as previously described 
(15,18). 
Results are expressed as the mean value + SE. The 
differences in the mean values among the three time points 
were assessed by two-way repeated measures analysis of vari- 
ance followed by the Tukey-Kramer method (21). Significant 
differences were recognized at p < 0.05. 
Resu l ts  
Clinical and ECG findings. Aminophylline significantly 
prolonged the time to the exercise nd point and significantly 
reduced maximal ST segment depression (Table 1). All 12 
patients experienced anginal pain during the placebo test, but 
pain was abolished in 7 and decreased in 5 during the 
aminophylline t st. 
Hemodynamic findings. Aminophylline increased the aver- 
age rate-pressure product at the overshoot but not at rest or at 
the end point and significantly increased the average jection 
fraction at rest (Table 2). However, aminophylline did not 
affect ejection fraction at the end point or at overshoot. 
Plot of time course of ejection fraction. The left ventricular 
ejection fraction-exercise time curve (Fig. 1) shifted upward 
and to the right after aminophylline. Average jection fraction 
at end point decreased significantly compared with ejection 
fraction at rest after both placebo and aminophylline (p < 0.05 
and p < 0.02, respectively); the patterns of the responses were 
similar during the placebo and aminophylline tests. Amino- 
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Table 2. Hemodynamic Variables After Aminophylline or Placebo Infusion 
RPP: Rest RPP: EP RPP: OS EF: Rest EF: EP EF: OS 
Pt No. Placebo Amino Placebo Amino Placebo Amino Placebo Amino Placebo Amino Placebo Amino 
1 12.3 14.;7 28.7 31.4 20.4 24.2 60.7 77.6 57.8 65.6 80.6 84.3 
2 6.3 7.2 20.3 24.4 11.0 14.6 61.6 68.1 65.0 68.5 85.4 77.4 
3 10.2 11.2 " 22.5 23.3 13.7 15.4 67.3 71.3 68.9 64.2 81.7 86.5 
4 6.1 6.0 22.6 23.0 9.1 9.2 57.4 58.1 48.7 49.4 84.9 85.0 
5 6.4 6.9 25.5 29.6 13.1 14.6 66.8 66.3 76.7 72.7 90.1 96.9 
6 9.5 7.3 26.3 21.3 11.3 12.7 67.0 66.9 50.5 62.0 78.2 91.2 
7 10.7 9.4 32.0 30.7 14.0 15.0 60.4 61.8 57.2 51.2 83.1 79.8 
8 7.6 7.9 32.8 34.9 15.7 17.4 58.1 65.3 57.4 59.1 94.2 88.9 
9 10.3 11.9 24.6 29.5 11.4 16.7 67.4 67.0 47.6 49.4 79.6 75.2 
10 10.2 10.0 21.7 24.5 11.4 13.3 55.7 57.2 53.0 52.8 68.8 67.8 
11 6.6 8.5 25.3 25.4 10.7 11.1 64.4 67.6 47.9 74.6 71.7 87.4 
12 10.1 10.7 20.4 20.8 14.4 16.4 60.7 71.2 48.2 52.1 77.2 78.4 
Mean 8.9 9.3 25.2 26.6 13.0 15.1 62.3 66.5 56,6 60.1 81.3 83.2 
-+SE +0.6 -+0.7 +1.2 -+1.3 -+0.9 -+1.1 +1.2 -+1.6 +2.7 -+2.6 -+2.1 -+2.3 
p value NS NS < 0.01 < 0.05 NS NS 
EF = ejection fraction; RPP = rate-pressure product; other abbreviations as in Table 1. 
phylline significantly prolonged exercise duration but did not 
change the time from the end point to overshoot (aminophyl- 
line 115 + 7 s vs. placebo 130 _+ 8 s, p = NS). 
There were no significant occurrences of induced prema- 
ture atrial or ventricular contractions and no significant 
increases in baseline heart rate or blood pressure or in 
symptoms, uch as nausea nd headache, after aminophylline. 
Discuss ion  
In the present study, we showed that aminophylline infusion 
increased effort olerance and ischemic threshold in 12 patients 
with syndrome X but did not improve the impaired left 
ventricular functional reserve or the delayed overshoot in the 
recovery period. 
Mechanism of action of aminophylline. Endogenous aden- 
osine plays a major role in the distribution of myocardial blood 
Figure 1. Changes in ejection fraction (EF) after aminophylline or




• Aminophyll ine 
80 0 Placebo / /  
/ /  
70 Ro , // 
60 " 
P 
50-  | , , , , , , ' i ** ,i ~ , , 
0 100 200 300 400 500 • 600 
Exercise Time (s) 
flow from the endocardium to the epicardium by mediating 
coronary vascular resistance (22,23). It has been demonstrated 
(1-5) that adenosine can trigger transmural coronary steal 
during exercise in patients with coronary artery disease. 
Aminophylline, a potent antagonist of adenosine Pl-receptors 
and stimulator of alphal-receptors, may exert an antisteal 
action. Through adenosine receptor blockade, aminophylline 
attenuates excessive hyperemia in relatively well perfused 
areas by blocking adenosine-mediated vasodilation during 
exercise (24). Through stimulation of coronary alphas- 
receptors and the resulting vasoconstriction f well perfused 
areas, aminophylline may increase perfusion pressure to poorly 
perfused areas (25,26). This is known as the Robin Hood effect 
in ischemic myocardium (1,14). 
Effect of ischemic threshold and exercise tolerance. Al- 
though the study populations differ, our data are consistent 
with recent reports (1-5) showing that aminophylline delays 
the onset of exercise-induced ischemia and increased effort 
tolerance in patients with coronary artery stenosis. Emdin et al. 
(13) reported prolonged exercise duration and increased rate- 
pressure product at peak exercise or at 0.1-mV ST segment 
depression i  a double-blind study of intravenous aminophyl- 
line in eight patients with syndrome X. They reported that 
exercise test results were negative by ECG criteria in all eight 
patients and that chest pain was abolished in three of the eight 
patients after aminophylline. The results of the present study 
are consistent with those of the report of Emdin et al. 
regarding chest pain, but they differ with respect o ECG 
findings. In our 12 patients, maximal ST segment depression 
was significantly diminished, but all test results were still 
positive by ECG criteria after aminophylline. Crea et al. (27) 
demonstrated that aminophylline markedly decreased the se- 
verity of chest pain despite not affecting the degree of ST 
segment depression at peak exercise in patients with coronary 
artery disease. These data, as well as those from the present 
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study, suggest that aminophylline has varying effects on chest 
pain and ECG findings depending on the dosage used (5) or 
the study subjects, possibly because of different receptors or 
thresholds. 
Effect of left ventrienlar functional reserve. We previously 
demonstrated (15) in patients with syndrome X undergoing 
exercise stress that left ventricular function is well preserved 
before ST segment depression but deteriorates increasingly in 
proportion to the degree of ST segment depression and that 
reduced left ventricular function persists into the recovery 
period. The interval from the end of exercise to the overshoot 
was significantly longer in patients than in control subjects 
(118 vs. 65 s, p < 0.01). 
In the present study, aminophylline increased ejection 
fraction at rest by 4.2% without increasing heart rate or blood 
pressure but did not preserve left ventricular ejection fraction 
during exercise. By subtracting 60.1% at the end point after 
aminophylline from 56.6% at the same point after placebo, we 
estimated that only -3.5% of the increase in ejection fraction 
might have been brought about by the antisteal action of 
aminophylline during exercise. These data showed the limita- 
tion of the beneficial effect of aminophylline on left ventricular 
functional reserve. Furthermore, although we did not examine 
the effect of aminophylline on normal subjects or on patients 
with ischemic heart disease, it is possible that the increase in 
ejection fraction at the end point may be a general rather than 
a specific effect on patients with ischemic heart disease or 
syndrome X. This is in agreement with the observation that 
aminophylline increases myocardial contractility inthe absence 
of increased afterload in healthy volunteers or conscious dogs 
(28-30). 
Previous tudies (18,31) have demonstrated that a delayed 
ejection fraction overshoot during recovery from exercise is a 
sensitive indicator of myocardial ischemia. Our data indicate 
that aminophylline does not affect left ventricular contractility 
during the recovery period once myocardial ischemia occurs. 
Clinical implications. The results of the present study not 
only show the effects of aminophylline infusion in patients with 
syndrome X, but also support the adenosine hypothesis of 
ischemic anginal pain suggested by Maseri et al. (32), who 
proposed that stimulation of adenosine receptors was likely to 
be primarily responsible for inducing cardiac pain and partially 
responsible for anginal pain during myocardial ischemia. The 
results also suggest that the effect of aminophylline on anginal 
pain is independent of the effect on exercise capacity. If this 
were true, one would expect a dissociation between anginal 
pain or exercise capacity and left ventricular responsiveness in 
patients with syndrome X or coronary artery disease. Indeed, 
the finding that aminophylline significantly reduced the sever- 
ity of exercise-induced chest pain and significantly improved 
exercise capacity without altering the response pattern of left 
ventricular ejection fraction during ischemia supports this 
dissociation. 
Conclusions. Before oral preparations of aminophylline 
can be adopted as major therapeutic options for patients with 
syndrome X, further assessment of the short- and long-term 
effects of this drug on cardiac functional reserve, ischemic 
threshold and exercise tolerance is required. 
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